vertex suzetrigine - Search News

FDA Approves 1st Non-Opioid Pain Drug in 20 Years

Scientific American · 3d

What Is Journavx, the New Opioid-Free Painkiller from Vertex?

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment

Time on MSN · 2h

FDA Approves the First Non-Opioid Pain Medicine in 20 Years

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non-opioid painkiller since that class first appeared on the market in the 1980s.

BioSpace · 3d

FDA Approves Vertex’s Journavx as First New Pain Drug in Decades

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum in the fledgling non-opioid pain space.

18h

Vertex Pharmaceuticals: Strong Buy Rating Driven by Suzetrigine Approval and Promising Market Prospects

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...

AFP3d

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

4hon MSN

Can new drug promise pain relief without peril?

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

15h

Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming ...

Vertex: Maintaining Buy Despite Tempered Expectations For Journavx In Pain

Vertex's Journavx got FDA approval for acute pain but faces adoption challenges. Click here to read more about VRTX stock and ...

Zacks.com on MSN10h

Vertex (VRTX) Surges 5.3%: Is This an Indication of Further Gains?

Vertex (VRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

11hon MSN

Vertex stock price target raised to $550 at H.C. Wainwright

H.C. Wainwright analyst Andrew Fein increased the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $550 from the previous $535, while maintaining a Buy rating on the stock.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results